1) we need NEW validated leads
2) we need clinical progress of VP-001
Stepping back as a third party observer - a fair read by the market on us = underwhelmed; slow, no surprise progress updates, milestones communicated via presentations still pending/delayed
as a shareholder - maybe I suffer from confirmation bias, but I believe 1st quarter 2022 is where we’ll hit some concrete milestones and deliver:
- 2 NEW validated leads which we will be confirmed to be taken to clinical via an aggressive parallel timeframe
- VP-001 announced milestones hit
- PYC extends platform to be a CNS pre-clinical player
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.020(1.77%) |
Mkt cap ! $670.7M | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.18 | $1.11 | $172.3K | 151.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 592 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 4211 | 1 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |